Vebreltinib plus PLB1004 for EGFR-mutant lung cancer with MET changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (stage IIIB to IV) with an EGFR mutation (exon 19 deletion or L858R).
- Your cancer has MET amplification or MET overexpression after you have taken an EGFR-targeted drug like gefitinib or osimertinib.
- You are at least 18 years old.
- You have not taken any MET inhibitor or HGF-targeted therapy before.
- You do not have ALK or ROS1 gene changes.
- You are able to do daily activities with little or no help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (vebreltinib and PLB1004) as the first treatment for people with a specific type of advanced lung cancer that has both an EGFR mutation and high MET protein. It may offer a new option for those who haven't had treatment yet.
This trial tests a combination of two experimental drugs (vebreltinib plus PLB1004) against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR mutation positive, MET positive) that has gotten worse after prior EGFR-targeted therapy.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
This trial tests PLB1004, an oral medication that targets a specific gene mutation (EGFR) in non-small cell lung cancer. It may be an option if you have this mutation and are looking for a new treatment.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.